Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$140.37
▼ $0.55 (-0.4%)
Market data updated: 09/19 04:40 PM
Fundamentals updated: 09/19/2026
News analyzed: 09/19/2026
Market Cap
$267.85B
Day Range
$139.60 - $141.15
52-Week Range
$121.57 - $170.46
Beta
—
Next Earnings
27.10.2026
Support
$137.00
Resistance
$164.48
NVS is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+14.8% (1Y)
Strengths: 8/29 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🔴 Bearish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
DCF Fair Value
Estimated fair value: $167.91 vs. price $140.37 (+19.6%)
Fair Value
Biggest negative driver
Price vs. SMA 50
Price is below the 50-day average
Technical
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
55
Today
—
30D
—
90D
—
1Y
🕰️ Signal Timeline
What StockIQ actually saw for this stock, and what happened after each signal — real data, not a forecast.
11d ago · $137.81
Evidence: Panic-selling score jumped from 11 to 51 day-over-day
What happened after
15d ago · $163.09
Evidence: FOMO score jumped from 11 to 45 day-over-day
What happened after
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🕰️ StockIQ Time Machine
What did StockIQ know — and when? Pick a date from the real accumulated history.
As of August 26, 2026
Then
68
$159.98
Now
55
$140.37
What happened since
Signals detected by this date
No signals detected by this date
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
65
Quality
50
Value
62
Momentum
13
Risk
50
Sentiment
98
Fundamental
75
Institutional
13
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Novartis AG has centered on mixed clinical trial results and strategic shifts. The company faced setbacks with its **pelacarsen** study failing to meet cardiovascular event reduction targets, erasing potential **$4.9 billion** in value and raising concerns about its cardiovascular pipeline. Meanwhile, Novartis reported progress on **delpacibart etedesiran** for myotonic dystrophy type 1, though it missed its primary endpoint, while **remibrutinib** for multiple sclerosis remains a high-stakes opportunity, with estimates suggesting a **$3 billion-plus** peak sales potential. Additionally, Novartis expanded its cardiovascular portfolio through a **$132 million** acquisition of Pfizer brands.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Novartis AG. News trend score: 98. Reason: 11 of the last 20 articles are positive, versus 3 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
27
🎯 Conviction (vs. Emotion)
50
Psychology
52
Fundamentals
75
Technical
13
Valuation
62
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
Price (3M)
-5%
Market Narrative
41
Fundamental Reality
50
Narrative Gap
-9
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The market behavior here is dominated by anchoring, as the stock trades perilously close to support (0.5% away), implying traders may be fixated on this level despite weak momentum and negative sentiment. The narrative gap (-32) further suggests a disconnect between market perception (low confidence) and reality (potential undervaluation). Herding and panic selling are secondary, likely reflecting relative underperformance and cautious liquidation. The key question remains whether traders will hold or break below support, given the lack of euphoria or overconfidence to sustain rallies.
Updated: 09/09/2026, 06:58 AM
What could change this?
👥 What the crowd believes
"Novartis shares fall as del-desiran flunks Phase 3 myotonic dystrophy trial"
"delpacibart etedesiran (del-desiran) Phase III HARBOR study... did not meet its primary endpoint"
"Novartis’s Pipeline Just Lost Two Big Bets"
"Novartis India acquires Pfizer brands for $132m — The purchase adds an established hypertension brand"
🧠 Market Brain events driving this
📈 14D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Samuel Armstrong Nelson — 90/100
🔴 Weakest match
Benjamin Graham (Enterprising Investor) — 11/100
🗣️ Why do they disagree?
This stock sparks a sharp divide among methodologies, with some seeing it as a compelling opportunity while others flag it as risky or overvalued. The highest-scoring approaches—Charles Mackay’s crowd psychology analysis and Samuel Armstrong Nelson’s cycle positioning—both suggest it’s a low-risk, favorable setup, as neither detects mania nor finds it overextended. Meanwhile, growth-oriented investors like Peter Lynch and Jack Schwager also rate it positively, emphasizing its potential for underappreciated upside, though with varying degrees of enthusiasm. In contrast, stricter value investors like Benjamin Graham and Walter Bagehot dismiss it outright, citing weak defensive metrics and liquidity concerns, while trend-followers like Jesse Livermore and Gerald Loeb warn of structural risks or downside threats. The divide highlights a tension between cyclical/growth optimism and traditional value or defensive caution, with even the most bullish methodologies (like Fisher or Marks) tempering their endorsements with caveats about quality or risk.
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 90
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 80
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟢 74
Looks like a real 'buy and hold for a decade' candidate
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟢 72
Growth candidate — the price hasn't caught up to the growth
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟢 65
Risk appears reasonably priced — no obvious cycle-timing red flag
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 58
Solid, but not the exceptional quality Fisher looked for
Key question
How exceptional is this business, really?
⚠️ Partial data for this stock — score is less reliable — Data availability: 35%
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 58
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟡 56
Somewhere in the middle of the cycle
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🟡 51
Moderate — holdable, but not effortless
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟡 47
Mixed signal on whether growth translates to real profit
Key question
Is management building real value, or just building itself?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 43
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 39
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🔴 33
Fails most of Graham's defensive criteria
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🔴 27
Liquidity position Bagehot would flag as a real risk
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🔴 13
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🔴 11
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
Fact → Principle → Simulation
Based on the last 282 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (0 bullish · 10 bearish · 1 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear downtrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
75.8%
Operating Margin
31.1%
Net Margin
24.8%
EBITDA Margin
—
ROE
30.3%
ROA
12.6%
ROIC
—
EPS
$7.21
Cash
$11.44B
Total Debt
—
Current Ratio
1.12
Debt/Equity
0.77
אין נתונים היסטוריים זמינים.
Total dividend per share paid each year, over the last 5 years.
| Ex-Dividend Date | Amount per Share |
|---|---|
| 11.3.2026 | $4.773 |
| 10.3.2026 | $4.773 |
| 12.3.2025 | $3.994 |
| 11.3.2025 | $3.994 |
| 7.3.2024 | $3.740 |
| 6.3.2024 | $3.740 |
| 9.3.2023 | $3.469 |
| 8.3.2023 | $3.469 |
| 8.3.2022 | $3.357 |
| 7.3.2022 | $3.357 |
How is Fair Value calculated? →
Current Price
$140.37
Estimated Fair Value (DCF)
$167.91
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
+19.6%
🟢 Appears cheap relative to estimated value
Year 1 Growth Rate
10.0%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 10.0% | $19.36B | $17.76B |
| 2 | 8.1% | $20.93B | $17.61B |
| 3 | 6.3% | $22.24B | $17.17B |
| 4 | 4.4% | $23.21B | $16.44B |
| 5 | 2.5% | $23.79B | $15.46B |
Base FCF (last actual year)
$17.60B
Terminal Value
$375.14B
Present Value of Terminal Value
$243.81B
Enterprise Value
$328.26B
Net Debt
$0
Equity Value
$328.26B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$24.18
Tangible Book Value per Share (Tangible NAV)
$8.76
Sentiment based on basic keywords (not AI) — 11 positive, 6 neutral, 3 negative out of the last 20 articles.
Yahoo · 18.9.2026
Yahoo · 18.9.2026
Yahoo · 18.9.2026
Yahoo · 18.9.2026
Benzinga · 18.9.2026
Yahoo · 18.9.2026
SeekingAlpha · 18.9.2026
Yahoo · 18.9.2026
Yahoo · 17.9.2026
Yahoo · 17.9.2026
Yahoo · 17.9.2026
Benzinga · 17.9.2026
Yahoo · 17.9.2026
Yahoo · 16.9.2026
Yahoo · 16.9.2026
Yahoo · 16.9.2026
Yahoo · 16.9.2026
Yahoo · 16.9.2026
Yahoo · 16.9.2026
Yahoo · 16.9.2026
Novartis AG (NVS) currently has a StockIQ AI score of 55/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
NVS currently scores 55/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, NVS's estimated fair value is $167.91, which is 19.6% above the current price of $140.37. This is one valuation model among several signals in the fair-value category, not a price target.
NVS's technical score is 13/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Estimated fair value: $167.91 vs. price $140.37 (+19.6%); Earnings per share (EPS) growth: 21.8%; Return on equity (ROE): 30.3% — strong.
Based on the real signals StockIQ computed: Price is below the 50-day average; Price is below the 200-day average; MACD histogram is negative — falling momentum.
Yes — NVS has a real recorded dividend payment history on StockIQ. See the Dividends section on this page for the actual per-share amounts and dates.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 2 purchases and 14 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| NOVARTIS PHARMA AG | Conversion of Derivative Security | 14.7.2020 | 7,367,387 | -7,367,387 | — |
| NOVARTIS PHARMA AG | Conversion of Derivative Security | 14.7.2020 | 5,908,089 | +5,908,089 | — |
| Novartis Bioventures Ltd | Conversion of Derivative Security | 30.6.2020 | 199,996 | -199,996 | — |
| Novartis Bioventures Ltd | Conversion of Derivative Security | 30.6.2020 | 856,262 | -856,262 | — |
| Novartis Bioventures Ltd | Open Market Purchase | 30.6.2020 | 125,000 | +125,000 | $17.00 |
| Novartis Bioventures Ltd | Conversion of Derivative Security | 30.6.2020 | 199,996 | +199,996 | — |
| Novartis Bioventures Ltd | Conversion of Derivative Security | 30.6.2020 | 856,262 | +856,262 | — |
| Novartis Bioventures Ltd | Open Market Sale | 19.6.2020 | 1,001,312 | -1,001,312 | $8.25 |
| Novartis Bioventures Ltd | Open Market Sale | 18.6.2020 | 900 | -900 | $9.04 |
| Novartis Bioventures Ltd | Open Market Sale | 17.6.2020 | 4,622 | -4,622 | $9.27 |
| Novartis Bioventures Ltd | Open Market Sale | 16.6.2020 | 8,600 | -8,600 | $9.30 |
| Novartis Bioventures Ltd | Open Market Sale | 15.6.2020 | 6,164 | -6,164 | $9.05 |
| Novartis Bioventures Ltd | Open Market Sale | 12.6.2020 | 1,500 | -1,500 | $9.19 |
| Novartis Bioventures Ltd | Open Market Sale | 11.6.2020 | 7,200 | -7,200 | $9.21 |
| Novartis Bioventures Ltd | Open Market Sale | 10.6.2020 | 8,532 | -8,532 | $9.46 |
| Novartis Bioventures Ltd | Open Market Sale | 9.6.2020 | 7,000 | -7,000 | $9.38 |
| Novartis Bioventures Ltd | Open Market Sale | 8.6.2020 | 5,659 | -5,659 | $9.66 |
| Novartis Bioventures Ltd | Open Market Sale | 5.6.2020 | 8,652 | -8,652 | $9.66 |
| Novartis Bioventures Ltd | Open Market Sale | 4.6.2020 | 4,088 | -4,088 | $9.55 |
| Novartis Bioventures Ltd | Open Market Sale | 3.6.2020 | 5,208 | -5,208 | $9.78 |
| Novartis Bioventures Ltd | Open Market Sale | 2.6.2020 | 5,669 | -5,669 | $9.68 |
| Novartis Bioventures Ltd | Conversion of Derivative Security | 12.11.2019 | 7,200,000 | -7,200,000 | — |
| Novartis Bioventures Ltd | Conversion of Derivative Security | 12.11.2019 | 451,609 | -451,609 | — |
| Novartis Bioventures Ltd | Conversion of Derivative Security | 12.11.2019 | 9,000,000 | -9,000,000 | — |
| Novartis Bioventures Ltd | Open Market Purchase | 12.11.2019 | 250,000 | +250,000 | $12.00 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
5,625,158 shares short as of 2026-08-31 · vs. 5,240,722 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
29.9% of trading volume this week was short selling, vs. 43.6% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology